Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-30T01:47:10.511Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of ziprasidone in patients with schizophrenia in four European countries

Published online by Cambridge University Press:  16 April 2020

J.-M. Montes
J.-M. Montes*
Affiliation:
Hospital del Sureste, Arganda del Rey, Spain
*
*Corresponding author. Tel.: +34 918394009; fax: +34 918394287. [email protected]
Get access

Abstract

Purpose

To characterise patients with schizophrenia from four European countries treated with ziprasidone, and to compare these with patients treated with other second generation antipsychotics (SGAs) included in this survey.

Method

A randomly selected, representative sample of psychiatrists (N = 744), from Germany, Greece, Italy and Spain, collected data on the five last patients with schizophrenia they had seen in consultation (N = 3996), including up to two patients treated with ziprasidone (N = 1096).

Results

Ziprasidone was most frequently prescribed to patients requiring a switch from another antipsychotic. Compared to other surveyed SGAs, ziprasisone was more likely to be prescribed to women than to men (OR: 1.52), to patients with mild disease than to those with severe disease (OR: 1.94) and to outpatients than to inpatients (1.30). The most frequently cited reasons for prescribing ziprasidone were good tolerability and efficacy against positive and negative symptoms. Compared to other SGAs included in this survey, it was more likely to be prescribed due to the low risk of weight gain, metabolic syndrome and extrapyramidal symptoms.

Conclusion

Patients treated by ziprasidone more frequently belong to subgroups composed of more autonomous patients and those with mild to moderate disease severity.

Keywords

SchizophreniaTreatmentZiprasidoneAntipsychoticPatient segmentation
Type
Research Article
Information
European Psychiatry , Volume 26 , Issue S1: Patients with schizophrenia: Results of a physician-based survey conducted in four European countries (Germany, Greece, Italy and Spain) , March 2011 , pp. 29 - 37
Copyright
Copyright © European Psychiatric Association 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Summary of product characteristics. Zeldox capsules; hard. Läkemedesverket. Swedish Medical Products Agency; 1998.Google Scholar
Summary of product characteristics: ZELDOX 20 mg/ml powder and solvent for solution for injection. Läkemedelsverket. Swedish Medical Products Agency; 2000.Google Scholar
Fagiolini, A.Cañas, F.Gallhofer, B.Larmo, I.Levy, P.Montes, J.M.Strategies for successful clinical management of schizophrenia with ziprasidone Expert Opin Pharmacother 11 2010 2199–2220CrossRefGoogle ScholarPubMed
Correll, C.U.Cañas, F.Larmo, I.Levy, P.Montes, J.M.Fagiolini, A.Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups Eur Psychiatry 26 2011 3–16CrossRefGoogle ScholarPubMed
Papageorgiou, G.Cañas, F.Zink, M.Rossi, A.Country differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in Europe Eur Psychiatry 26 2011 17–28CrossRefGoogle ScholarPubMed
P. Gorwood Factors associated with hospitalisation of patients with schizophrenia in four European countries. Eur Psychiatry 2011. [In press].CrossRefGoogle Scholar
Citrome, L.Yang, R.Glue, P.Karayal, O.N.Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials Schizophr Res 111 2009 39–45CrossRefGoogle ScholarPubMed
Mamo, D.Kapur, S.Shammi, C.M.Papatheodorou, G.Mann, S.Therrien, F.A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone Am J Psychiatry 161 2004 818–825CrossRefGoogle ScholarPubMed
Jones, P.B.Barnes, T.R.Davies, L.Dunn, G.Lloyd, H.Hayhurst, K.P.Randomized controlled trial of the effect on Quality of Life of secondvs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry 63 2006 1079–1087CrossRefGoogle Scholar
Lieberman, J.A.Stroup, T.S.McEvoy, J.P.Swartz, M.S.Rosenheck, R.A.Perkins, D.O.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 2005 1209–1223CrossRefGoogle ScholarPubMed
Weiden, P.J. Switching in the era of atypical antipsychotics. An updated review Postgrad Med 2006 27–44 Spec NoGoogle Scholar
Rossi, A.Vita, A.Tiradritti, P.Romeo, F.Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone Int Clin Psychopharmacol 23 2008 216–222CrossRefGoogle ScholarPubMed
Kingsbury, S.J.Fayek, M.Trufasiu, D.Zada, J.Simpson, G.M.The apparent effects of ziprasidone on plasma lipids and glucose J Clin Psychiatry 62 2001 347–349CrossRefGoogle ScholarPubMed
Weiden, P.J.Simpson, G.M.Potkin, S.G.O’Sullivan, R.L.Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia J Clin Psychiatry 64 2003 580–588CrossRefGoogle ScholarPubMed
Kim, S.W.Shin, I.S.Kim, J.M.Bae, K.Y.Yang, S.J.Yoon, J.S.Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia Clin Neuropharmacol 33 2010 121–125CrossRefGoogle ScholarPubMed
Weiden, P.J.Newcomer, J.W.Loebel, A.D.Yang, R.Lebovitz, H.E.Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone Neuropsychopharmacology 33 2008 985–994CrossRefGoogle ScholarPubMed
Garman, P.M.Ried, L.D.Bengtson, M.A.Hsu, C.McConkey, J.R.Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia J Am Pharm Assoc 47 2007 373–378CrossRefGoogle ScholarPubMed
Ried, L.D.McConkey, J.R.Bengtson, M.A.Garman, P.M.Hsu, C.Rahnavard, F.Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia-related disorders J Am Pharm Assoc 47 2007 156–164CrossRefGoogle Scholar
Montes, J.M.Rodriguez, J.L.Balbo, E.Sopelana, P.Martin, E.Soto, J.A.Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone Prog Neuropsychopharmacol Biol Psychiatry 31 2007 383–388CrossRefGoogle ScholarPubMed
Rossi, A.Cañas, F.Fagiolini, A.Larmo, I.Levy, P.Montes, J.M.Switching among antipsychotics in everyday clinical practice: focus on ziprasidone Postgraduate Medicine 123 2011 135–159CrossRefGoogle ScholarPubMed
Kahn, R.S.Fleischhacker, W.W.Boter, H.Davidson, M.Vergouwe, Y.Keet, I.P.Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial Lancet 371 2008 1085–1097CrossRefGoogle ScholarPubMed
Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, et al. Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial. Schizophr Bull 2009. [Published online: June 19, 2009 (doi:10-1093/schbul/sbpo37)].Google Scholar
De Hert, M.Dekker, J.M.Wood, D.Kahl, K.G.Holt, R.I.Möller, H.J.Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) Eur Psychiatry 24 2009 412–424CrossRefGoogle Scholar
Gandelman, K.Alderman, J.A.Glue, P.Lombardo, I.LaBadie, R.R.Versavel, M. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial J Clin Psychiatry 70 2009 58–62CrossRefGoogle Scholar
Citrome, L.Using oral ziprasidone effectively: the food effect and dose-response Adv Ther 26 2009 739–748CrossRefGoogle ScholarPubMed
Leucht, S.Corves, C.Arbter, D.Engel, R.R.Li, C.Davis, J.M.Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 2009 31–41CrossRefGoogle ScholarPubMed
Olié, J.P.Spina, E.Murray, S.Yang, R.Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study Int Clin Psychopharmacol 21 2006 143–151Google ScholarPubMed
Murphy, B.P.Chung, Y.C.Park, T.W.McGorry, P.D.Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review Schizophr Res 88 2006 5–25CrossRefGoogle ScholarPubMed
Rummel-Kluge, C.Komossa, K.Schwarz, S.Hunger, H.Schmid, F.Lobos, C.A.Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Schizophr Res 123 2010 225–233CrossRefGoogle ScholarPubMed
Newcomer, J.W.Antipsychotic medications: metabolic and cardiovascular risk J Clin Psychiatry 68 Suppl 4 2007 8–13Google ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinology, North American Association for the study of obesity Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care 272004 596–601Google Scholar
Summary of product characteristics. Zeldox capsules; hard. Läkemedesverket. Swedish Medical Products Agency; 1998.Google Scholar
Summary of product characteristics: ZELDOX 20 mg/ml powder and solvent for solution for injection. Läkemedelsverket. Swedish Medical Products Agency; 2000.Google Scholar
Fagiolini, A.Cañas, F.Gallhofer, B.Larmo, I.Levy, P.Montes, J.M.Strategies for successful clinical management of schizophrenia with ziprasidone Expert Opin Pharmacother 11 2010 2199–2220CrossRefGoogle ScholarPubMed
Correll, C.U.Cañas, F.Larmo, I.Levy, P.Montes, J.M.Fagiolini, A.Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups Eur Psychiatry 26 2011 3–16CrossRefGoogle ScholarPubMed
Papageorgiou, G.Cañas, F.Zink, M.Rossi, A.Country differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in Europe Eur Psychiatry 26 2011 17–28CrossRefGoogle ScholarPubMed
P. Gorwood Factors associated with hospitalisation of patients with schizophrenia in four European countries. Eur Psychiatry 2011. [In press].CrossRefGoogle Scholar
Citrome, L.Yang, R.Glue, P.Karayal, O.N.Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials Schizophr Res 111 2009 39–45CrossRefGoogle ScholarPubMed
Mamo, D.Kapur, S.Shammi, C.M.Papatheodorou, G.Mann, S.Therrien, F.A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone Am J Psychiatry 161 2004 818–825CrossRefGoogle ScholarPubMed
Jones, P.B.Barnes, T.R.Davies, L.Dunn, G.Lloyd, H.Hayhurst, K.P.Randomized controlled trial of the effect on Quality of Life of secondvs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry 63 2006 1079–1087CrossRefGoogle Scholar
Lieberman, J.A.Stroup, T.S.McEvoy, J.P.Swartz, M.S.Rosenheck, R.A.Perkins, D.O.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 2005 1209–1223CrossRefGoogle ScholarPubMed
Weiden, P.J. Switching in the era of atypical antipsychotics. An updated review Postgrad Med 2006 27–44 Spec NoGoogle Scholar
Rossi, A.Vita, A.Tiradritti, P.Romeo, F.Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone Int Clin Psychopharmacol 23 2008 216–222CrossRefGoogle ScholarPubMed
Kingsbury, S.J.Fayek, M.Trufasiu, D.Zada, J.Simpson, G.M.The apparent effects of ziprasidone on plasma lipids and glucose J Clin Psychiatry 62 2001 347–349CrossRefGoogle ScholarPubMed
Weiden, P.J.Simpson, G.M.Potkin, S.G.O’Sullivan, R.L.Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia J Clin Psychiatry 64 2003 580–588CrossRefGoogle ScholarPubMed
Kim, S.W.Shin, I.S.Kim, J.M.Bae, K.Y.Yang, S.J.Yoon, J.S.Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia Clin Neuropharmacol 33 2010 121–125CrossRefGoogle ScholarPubMed
Weiden, P.J.Newcomer, J.W.Loebel, A.D.Yang, R.Lebovitz, H.E.Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone Neuropsychopharmacology 33 2008 985–994CrossRefGoogle ScholarPubMed
Garman, P.M.Ried, L.D.Bengtson, M.A.Hsu, C.McConkey, J.R.Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia J Am Pharm Assoc 47 2007 373–378CrossRefGoogle ScholarPubMed
Ried, L.D.McConkey, J.R.Bengtson, M.A.Garman, P.M.Hsu, C.Rahnavard, F.Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia-related disorders J Am Pharm Assoc 47 2007 156–164CrossRefGoogle Scholar
Montes, J.M.Rodriguez, J.L.Balbo, E.Sopelana, P.Martin, E.Soto, J.A.Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone Prog Neuropsychopharmacol Biol Psychiatry 31 2007 383–388CrossRefGoogle ScholarPubMed
Rossi, A.Cañas, F.Fagiolini, A.Larmo, I.Levy, P.Montes, J.M.Switching among antipsychotics in everyday clinical practice: focus on ziprasidone Postgraduate Medicine 123 2011 135–159CrossRefGoogle ScholarPubMed
Kahn, R.S.Fleischhacker, W.W.Boter, H.Davidson, M.Vergouwe, Y.Keet, I.P.Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial Lancet 371 2008 1085–1097CrossRefGoogle ScholarPubMed
Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, et al. Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial. Schizophr Bull 2009. [Published online: June 19, 2009 (doi:10-1093/schbul/sbpo37)].Google Scholar
De Hert, M.Dekker, J.M.Wood, D.Kahl, K.G.Holt, R.I.Möller, H.J.Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) Eur Psychiatry 24 2009 412–424CrossRefGoogle Scholar
Gandelman, K.Alderman, J.A.Glue, P.Lombardo, I.LaBadie, R.R.Versavel, M. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial J Clin Psychiatry 70 2009 58–62CrossRefGoogle Scholar
Citrome, L.Using oral ziprasidone effectively: the food effect and dose-response Adv Ther 26 2009 739–748CrossRefGoogle ScholarPubMed
Leucht, S.Corves, C.Arbter, D.Engel, R.R.Li, C.Davis, J.M.Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 2009 31–41CrossRefGoogle ScholarPubMed
Olié, J.P.Spina, E.Murray, S.Yang, R.Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study Int Clin Psychopharmacol 21 2006 143–151Google ScholarPubMed
Murphy, B.P.Chung, Y.C.Park, T.W.McGorry, P.D.Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review Schizophr Res 88 2006 5–25CrossRefGoogle ScholarPubMed
Rummel-Kluge, C.Komossa, K.Schwarz, S.Hunger, H.Schmid, F.Lobos, C.A.Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Schizophr Res 123 2010 225–233CrossRefGoogle ScholarPubMed
Newcomer, J.W.Antipsychotic medications: metabolic and cardiovascular risk J Clin Psychiatry 68 Suppl 4 2007 8–13Google ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinology, North American Association for the study of obesity Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care 272004 596–601Google Scholar
Submit a response

Comments

No Comments have been published for this article.